Via Nova Therapeutics
Via Nova Therapeutics is dedicated to discovering and developing novel therapies for viral diseases, focusing on acute and subacute infections. They aim to leverage rapid diagnostics and innovative drug discovery modalities to bring effective treatments to the clinic, diverging from the traditional focus on chronic viral infections.
Industries
Nr. of Employees
small (1-50)
Via Nova Therapeutics
Products
Influenza A small-molecule nucleoprotein inhibitor (clinical candidate)
A novel small-molecule inhibitor directed against influenza A nucleoprotein with in vitro activity against seasonal and highly pathogenic avian influenza strains and activity against strains with resistance to existing therapies; advanced to IND clearance.
Human rhinovirus polymerase inhibitor (preclinical candidate)
Small-molecule inhibitor targeting the conserved viral RNA polymerase with coverage across the three major HRV clades, intended to prevent virus-triggered exacerbations in asthma and COPD.
BK polyomavirus small-molecule inhibitor
Small-molecule inhibitor active against all four genotypes of BK polyomavirus intended for prevention or treatment of BKV-induced renal disease post-kidney transplant; acts on an intracellular target rather than neutralizing antibody mechanisms.
Adenovirus replication inhibitor for ocular and systemic infections
Small-molecule inhibitor that disrupts adenovirus replication with activity against serotypes causing conjunctivitis and epidemic keratoconjunctivitis, intended for ocular infections and severe systemic disease in immunocompromised patients.
Influenza A small-molecule nucleoprotein inhibitor (clinical candidate)
A novel small-molecule inhibitor directed against influenza A nucleoprotein with in vitro activity against seasonal and highly pathogenic avian influenza strains and activity against strains with resistance to existing therapies; advanced to IND clearance.
Human rhinovirus polymerase inhibitor (preclinical candidate)
Small-molecule inhibitor targeting the conserved viral RNA polymerase with coverage across the three major HRV clades, intended to prevent virus-triggered exacerbations in asthma and COPD.
BK polyomavirus small-molecule inhibitor
Small-molecule inhibitor active against all four genotypes of BK polyomavirus intended for prevention or treatment of BKV-induced renal disease post-kidney transplant; acts on an intracellular target rather than neutralizing antibody mechanisms.
Adenovirus replication inhibitor for ocular and systemic infections
Small-molecule inhibitor that disrupts adenovirus replication with activity against serotypes causing conjunctivitis and epidemic keratoconjunctivitis, intended for ocular infections and severe systemic disease in immunocompromised patients.
Services
Internal discovery and development of small-molecule antiviral candidates from hit identification through IND-enabling studies and early clinical development.
Acquisition and integration of externally developed antiviral programs to form or expand a therapeutic pipeline.
Internal discovery and development of small-molecule antiviral candidates from hit identification through IND-enabling studies and early clinical development.
Acquisition and integration of externally developed antiviral programs to form or expand a therapeutic pipeline.
Expertise Areas
- Antiviral small-molecule discovery
- Virology (influenza, human rhinovirus, BK polyomavirus, adenovirus)
- Phenotypic and biochemical screening
- Structure-based drug design
Key Technologies
- Phenotypic screening in infected cells
- Biochemical enzymatic assays
- Structure-based drug design
- Small-molecule medicinal chemistry
News & Updates
Via Nova Therapeutics announced FDA clearance of its Investigational New Drug application for VNT-101, a novel antiviral against Influenza A.
The company announced FDA clearance for its Influenza A nucleoprotein inhibitor, VNT-101, marking a milestone in its development pipeline.
Via Nova Therapeutics announced FDA clearance of its Investigational New Drug application for VNT-101, a novel antiviral against Influenza A.
The company announced FDA clearance for its Influenza A nucleoprotein inhibitor, VNT-101, marking a milestone in its development pipeline.